# **Special Issue**

# Navigating the Evolving Landscape of Gynecology: From Diagnosis to Treatment

# Message from the Guest Editors

The landscape of gynecological oncology has been transformed by advancements in precision medicine and immunotherapy, ushering in a new era of personalized cancer care. From targeted molecular therapies to novel immunomodulatory agents, these groundbreaking treatments hold promise for improved outcomes and enhanced quality of life for women with gynecological malignancies.

In this update on gynecology, we embark on a comprehensive journey from diagnosis to treatment, exploring the latest advancements that shape the landscape of women's health care. By delving into the intricate interplay between cutting-edge diagnostics and innovative therapeutic modalities, we aim to provide insights into the evolving landscape of gynecological care and its profound impact on patient outcomes and well-being. Therefore, original articles, reviews, and meta-analyses are welcome in this Special Issue.

### **Guest Editors**

### Dr. Ferdinando Antonio Gulino

Department of Obstetrics and Gynaecology, Azienda di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Garibaldi Nesima, 95124 Catania, Italy

### Dr. Stefano Cianci

Department of Obstetrics and Gynecology, University of Messina, 98122 Messina, Italy

### Deadline for manuscript submissions

closed (15 July 2025)



# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



### mdpi.com/si/199542

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





# Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



# About the Journal

# Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. JPM publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). JPM is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

### **Editor-in-Chief**

### Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

### **Author Benefits**

# **High Visibility:**

indexed within Scopus, PubMed, PMC, Embase, and other databases.

### **Journal Rank:**

CiteScore - Q1 (Medicine (miscellaneous))

### **Rapid Publication:**

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

